MYCN and neuroblastoma: Gartlgruber et al. reported super-enhancers in comprehensive published dataset of 60 NB tumors and 25 cell lines14 and identified one consensus SOX11 super-enhancer (present in at least 2 samples, not overlapping with H3K4me3 and 5 kb away from a transcription start site), in the adrenergic NB subtype (MYCN amplified, high-risk MYCN non-amplified and low-risk MYCN non-amplified group), while absent or strongly attenuated in the mesenchymal super-enhancer defined group, both in cell lines (Fig. 2a and b, Supplementary Figure 2a–c) and tumors (Fig. 2a and c).